{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["12"],"submitter":["Kulanthaivelu R"],"pubmed_abstract":["<h4>Purpose</h4>Radiomics is an emerging imaging assessment technique that has shown promise in predicting survival among nasopharyngeal carcinoma (NPC) patients. Studies so far have focused on PET or MR-based radiomics independently. The aim of our study was to evaluate the prognostic value of clinical and radiomic parameters derived from both PET/CT and MR.<h4>Methods</h4>Retrospective evaluation of 124 NPC patients with PET/CT and radiotherapy planning MR (RP-MR). Primary tumors were segmented using dedicated software (LIFEx version 6.1) from PET, CT, contrast-enhanced T1-weighted (T1-w), and T2-weighted (T2-w) MR sequences with 376 radiomic features extracted. Summary statistics describe patient, disease, and treatment characteristics. The Kaplan-Meier (KM) method estimates overall survival (OS) and progression-free survival (PFS). Clinical factors selected based on univariable analysis and the multivariable Cox model were subsequently constructed with radiomic features added.<h4>Results</h4>The final models comparing clinical, clinical + RP-MR, clinical + PET/CT and clinical + RP-MR + PET/CT for OS and PFS demonstrated that combined radiomic signatures were significantly associated with improved survival prognostication (AUC 0.62 <i>vs</i> 0.81 <i>vs</i> 0.75 <i>vs</i> 0.86 at 21 months for PFS and 0.56 <i>vs</i> 0.85 <i>vs</i> 0.79 <i>vs</i> 0.96 at 24 months for OS). Clinical + RP-MR features initially outperform clinical + PET/CT for both OS and PFS (<18 months), and later in the clinical course for PFS (>42 months).<h4>Conclusion</h4>Our study demonstrated that PET/CT-based radiomic features may improve survival prognostication among NPC patients when combined with baseline clinical and MR-based radiomic features."],"journal":["Frontiers in oncology"],"pagination":["952763"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9638017"],"repository":["biostudies-literature"],"pubmed_title":["Prognostic value of PET/CT and MR-based baseline radiomics among patients with non-metastatic nasopharyngeal carcinoma."],"pmcid":["PMC9638017"],"pubmed_authors":["Hope A","Liu ZA","Ortega C","Kulanthaivelu R","Kohan A","Veit-Haibach P","Huang SH","Waldron J","Hinzpeter R","O'Sullivan B","Metser U"],"additional_accession":[]},"is_claimable":false,"name":"Prognostic value of PET/CT and MR-based baseline radiomics among patients with non-metastatic nasopharyngeal carcinoma.","description":"<h4>Purpose</h4>Radiomics is an emerging imaging assessment technique that has shown promise in predicting survival among nasopharyngeal carcinoma (NPC) patients. Studies so far have focused on PET or MR-based radiomics independently. The aim of our study was to evaluate the prognostic value of clinical and radiomic parameters derived from both PET/CT and MR.<h4>Methods</h4>Retrospective evaluation of 124 NPC patients with PET/CT and radiotherapy planning MR (RP-MR). Primary tumors were segmented using dedicated software (LIFEx version 6.1) from PET, CT, contrast-enhanced T1-weighted (T1-w), and T2-weighted (T2-w) MR sequences with 376 radiomic features extracted. Summary statistics describe patient, disease, and treatment characteristics. The Kaplan-Meier (KM) method estimates overall survival (OS) and progression-free survival (PFS). Clinical factors selected based on univariable analysis and the multivariable Cox model were subsequently constructed with radiomic features added.<h4>Results</h4>The final models comparing clinical, clinical + RP-MR, clinical + PET/CT and clinical + RP-MR + PET/CT for OS and PFS demonstrated that combined radiomic signatures were significantly associated with improved survival prognostication (AUC 0.62 <i>vs</i> 0.81 <i>vs</i> 0.75 <i>vs</i> 0.86 at 21 months for PFS and 0.56 <i>vs</i> 0.85 <i>vs</i> 0.79 <i>vs</i> 0.96 at 24 months for OS). Clinical + RP-MR features initially outperform clinical + PET/CT for both OS and PFS (<18 months), and later in the clinical course for PFS (>42 months).<h4>Conclusion</h4>Our study demonstrated that PET/CT-based radiomic features may improve survival prognostication among NPC patients when combined with baseline clinical and MR-based radiomic features.","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2025-04-19T23:15:04.97Z","creation":"2025-02-19T00:31:33.33Z"},"accession":"S-EPMC9638017","cross_references":{"pubmed":["36353565"],"doi":["10.3389/fonc.2022.952763"]}}